Spencer A - Search Results

1

The effect of azacitidine on interleukin-6 signaling and nuclear factor-kappaB activation and its in vitro and in vivo activity against multiple myeloma.

Khong T, Sharkey J, Spencer A. Khong T, et al. Among authors: spencer a. Haematologica. 2008 Jun;93(6):860-9. doi: 10.3324/haematol.12261. Epub 2008 Apr 28. Haematologica. 2008. PMID: 18443271 Free article.

2

Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma.

Baulch-Brown C, Molloy TJ, Yeh SL, Ma D, Spencer A. Baulch-Brown C, et al. Among authors: spencer a. Leuk Res. 2007 Mar;31(3):341-52. doi: 10.1016/j.leukres.2006.07.018. Epub 2006 Sep 22. Leuk Res. 2007. PMID: 16996129

3

PKC412 demonstrates JNK-dependent activity against human multiple myeloma cells.

Sharkey J, Khong T, Spencer A. Sharkey J, et al. Among authors: spencer a. Blood. 2007 Feb 15;109(4):1712-9. doi: 10.1182/blood-2006-05-014092. Epub 2006 Oct 10. Blood. 2007. PMID: 17032922 Free article.

4

Laboratory tumor lysis syndrome complicating LBH589 therapy in a patient with acute myeloid leukaemia.

Kalff A, Shortt J, Farr J, McLennan R, Lui A, Scott J, Spencer A. Kalff A, et al. Among authors: spencer a. Haematologica. 2008 Jan;93(1):e16-7. doi: 10.3324/haematol.11933. Haematologica. 2008. PMID: 18166770 Free article.

5

Clinical and immunohistochemical features associated with a response to bortezomib in patients with multiple myeloma.

Dawson MA, Opat SS, Taouk Y, Donovan M, Zammit M, Monaghan K, Horvath N, Roberts AW, Prince HM, Hertzberg M, McLean CA, Spencer A. Dawson MA, et al. Among authors: spencer a. Clin Cancer Res. 2009 Jan 15;15(2):714-22. doi: 10.1158/1078-0432.CCR-08-1022. Clin Cancer Res. 2009. PMID: 19147779

6

CYT997 causes apoptosis in human multiple myeloma.

Monaghan K, Khong T, Smith G, Spencer A. Monaghan K, et al. Among authors: spencer a. Invest New Drugs. 2011 Apr;29(2):232-8. doi: 10.1007/s10637-009-9350-5. Epub 2009 Nov 12. Invest New Drugs. 2011. PMID: 19907921

7

Deactylase inhibition in myeloproliferative neoplasms.

Mithraprabhu S, Grigoriadis G, Khong T, Spencer A. Mithraprabhu S, et al. Among authors: spencer a. Invest New Drugs. 2010 Dec;28 Suppl 1(Suppl 1):S50-7. doi: 10.1007/s10637-010-9590-4. Epub 2010 Dec 3. Invest New Drugs. 2010. PMID: 21127942 Free PMC article. Review.

8

The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.

Monaghan KA, Khong T, Burns CJ, Spencer A. Monaghan KA, et al. Among authors: spencer a. Leukemia. 2011 Dec;25(12):1891-9. doi: 10.1038/leu.2011.175. Epub 2011 Jul 26. Leukemia. 2011. PMID: 21788946

9

Targeting HSP 90 induces apoptosis and inhibits critical survival and proliferation pathways in multiple myeloma.

Khong T, Spencer A. Khong T, et al. Among authors: spencer a. Mol Cancer Ther. 2011 Oct;10(10):1909-17. doi: 10.1158/1535-7163.MCT-11-0174. Epub 2011 Aug 22. Mol Cancer Ther. 2011. PMID: 21859842

10

Histone deacetylase (HDAC) inhibitors as single agents induce multiple myeloma cell death principally through the inhibition of class I HDAC.

Mithraprabhu S, Khong T, Jones SS, Spencer A. Mithraprabhu S, et al. Among authors: spencer a. Br J Haematol. 2013 Aug;162(4):559-62. doi: 10.1111/bjh.12388. Epub 2013 May 21. Br J Haematol. 2013. PMID: 23692150 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,669 results

Search Page

Filters